Indications and uses
Temporarily relieves the symptoms of fatigue, pain and swelling in muscles,joints, back and limbs, muscle soreness and cramping.
BIOPLASMA SPORT WITH ELECTROLYTES
- Manufacturer
- Hyland's | Standard Homeopathic Company | MeriCal
- Effective date
- 2018-03-07
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 3
- Source
- full-release
- Hydrated at
- 2026-06-01 02:09:16
Label at a glance#
ProductBIOPLASMA SPORT WITH ELECTROLYTES
Active ingredientCALCIUM FLUORIDE, TRIBASIC CALCIUM PHOSPHATE, CALCIUM SULFATE ANHYDROUS, FERROSOFERRIC PHOSPHATE, POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, DIBASIC, MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE, SODIUM CHLORIDE, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE, SODIUM SULFATE, SILICON DIOXIDE
Label structure8 sections
Dosage and administration
Adults and children 7-12 years: Pour 1 packet directly on tongue without tilting head or inhaling. Close mouth. Powder will dissolve quickly. Each single-dose packet can also be dissolved into an 8 oz glass or bottle of water. Stir or shake to dissolve powder. Water may be sipped throughout activity. For best results, repeat every 3-4 hours as needed, before during or after activity. Children Ages 2-6 years: One-H...
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
OTC - ACTIVE INGREDIENT SECTION
OTC - PURPOSE SECTION
| Active Ingredients | Purpose |
| Calc Fluor 6X HPUS | backaches |
| Calc Phos 3X HPUS | pain in muscles & joints |
| Calc Sulph 3X HPUS | swelling |
| Ferrum Phos 3X HPUS | pain |
| Kali Mur 3X HPUS | sprains |
Kali Phos 3X HPUS | pain in back and limbs |
Kali Sulph 3X HPUS | pain in limbs |
Mag Phos 3X HPUS | muscle soreness; cramps |
Nat Mur 6X HPUS | pain in joints |
Nat Phos 3X HPUS | muscle soreness |
Nat Sulph 3X HPUS | pain in muscles |
Silicea 6X HPUS | fatigue |
“HPUS” indicates that the active ingredients are in the official Homeopathic Pharmacopœia of the United States.
Uses
Temporarily relieves the symptoms of fatigue, pain and swelling in muscles,joints, back and limbs, muscle soreness and cramping.
Warnings
OTC - PREGNANCY OR BREAST FEEDING SECTION
As with any drug, ask a doctor before use if pregnant or nursing.
OTC - ASK DOCTOR SECTION
Consult a physician if symptoms persist for more than 7 days or worsen.
OTC - DO NOT USE SECTION
Do not use if stick pack is broken or torn.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep this and all medications out of the reach of children. In case of accidental overdose contact a medical professional or Poison Control Center immediately.
In case of emergency, contact a medical proffessional or Poison Control Center immediately. Hyland's may be contacted 24 hours a day, 7 days a week at 800/624-9659.
Directions
Adults and children 7-12 years: Pour 1 packet directly on tongue without tilting head or inhaling. Close mouth. Powder will dissolve quickly. Each single-dose packet can also be dissolved into an 8 oz glass or bottle of water. Stir or shake to dissolve powder. Water may be sipped throughout activity. For best results, repeat every 3-4 hours as needed, before during or after activity. Children Ages 2-6 years: One-Half adult dose (packet).
Inactive Ingredients
Calcium lactate gluconate, citric acid USP/FCC, colloidal silicon dioxide, lactose NF C/S, magnesium citrate, mannitol USP, natural flavors, potassium sulfate, sodium citrate USP/FCC, sorbitol NF, stevia leaf extract.
Questions?
800/624-9659
PRINCIPAL DISPLAY PANEL - 12 Packet Carton
NDC 54973-3122-1
HOMEOPATHIC
Natural
Relief
Hyland's®
BIOPLASMA®
SPORT Citrust Flavor
Recover from
your toughest
workouts*
12 PACKETS (2g EACH) NET WT.24g
Dissolves on tongue or in water
Product Linked Resources#
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 0354973312210 | GTIN-13: 0354973312210 EAN-13: 0354973312210 GTIN-12: 354973312210 UPC-A: 354973312210 GTIN storage (14 digits): 00354973312210 | BIOS----W12.jpg |
| Data code | Code 128 | 01180403 | BIOS----W12.jpg |
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 54973-3122-2 | 2022-07-29 | C162847 | 48780-1 | e4f33bdf-b2bc-d8a0-e053-dadaa90a6e4e | BIOPLASMA ® SPORT WITH ELECTROLYTES |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 54973-3122-1 | BIOPLASMA SPORT WITH ELECTROLYTES | 2 g in 1 PACKET | POWDER | 2 | 3 | |
| 54973-3122-2 | BIOPLASMA SPORT WITH ELECTROLYTES | 12 in 1 CARTON | POWDER | 12 | 3 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 54973-3122 | BIOPLASMA SPORT WITH ELECTROLYTES (CALCIUM FLUORIDE, TRIBASIC CALCIUM PHOSPHATE, CALCIUM SULFATE ANHYDROUS, FERROSOFERRIC PHOSPHATE, POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, DIBASIC, MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE, SODIUM CHLORIDE, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE, SODIUM SULFATE, AND SILICON DIOXIDE) POWDER [HYLAND'S] | 3 | Legacy NDC, 2 package rows | 20180307_cd808cfb-9bc5-453f-9f54-f568c16f3df3.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CALCIUM FLUORIDE | ACTIVE INGREDIENT | O3B55K4YKI | 1 | |
| CALCIUM SULFATE ANHYDROUS | ACTIVE INGREDIENT | E934B3V59H | 1 | |
| FERROSOFERRIC PHOSPHATE | ACTIVE INGREDIENT | 91GQH8I5F7 | 1 | |
| MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE | ACTIVE INGREDIENT | HF539G9L3Q | 1 | |
| POTASSIUM CHLORIDE | ACTIVE INGREDIENT | 660YQ98I10 | 1 | |
| POTASSIUM PHOSPHATE, DIBASIC | ACTIVE INGREDIENT | CI71S98N1Z | 1 | |
| SILICON DIOXIDE | ACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| SODIUM CHLORIDE | ACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE | ACTIVE INGREDIENT | 70WT22SF4B | 1 | |
| SODIUM SULFATE | ACTIVE INGREDIENT | 0YPR65R21J | 1 | |
| TRIBASIC CALCIUM PHOSPHATE | ACTIVE INGREDIENT | 91D9GV0Z28 | 1 | |
| CALCIUM CATION | ACTIVE MOIETY | 2M83C4R6ZB | 1 | |
| CHLORIDE ION | ACTIVE MOIETY | Q32ZN48698 | 1 | |
| FERROSOFERRIC PHOSPHATE | ACTIVE MOIETY | 91GQH8I5F7 | 1 | |
| FLUORIDE ION | ACTIVE MOIETY | Q80VPU408O | 1 | |
| MAGNESIUM CATION | ACTIVE MOIETY | T6V3LHY838 | 1 | |
| PHOSPHATE ION | ACTIVE MOIETY | NK08V8K8HR | 1 | |
| SILICON DIOXIDE | ACTIVE MOIETY | ETJ7Z6XBU4 | 1 | |
| SODIUM CATION | ACTIVE MOIETY | LYR4M0NH37 | 1 | |
| SODIUM SULFATE ANHYDROUS | ACTIVE MOIETY | 36KCS0R750 | 1 | |
| ANHYDROUS CITRIC ACID | INACTIVE INGREDIENT | XF417D3PSL | 1 | |
| CALCIUM CATION | INACTIVE INGREDIENT | 2M83C4R6ZB | 1 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 1 | |
| MAGNESIUM CATION | INACTIVE INGREDIENT | T6V3LHY838 | 1 | |
| MANNITOL | INACTIVE INGREDIENT | 3OWL53L36A | 1 | |
| SORBITOL | INACTIVE INGREDIENT | 506T60A25R | 1 | |
| STEVIA REBAUDIUNA LEAF | INACTIVE INGREDIENT | 6TC6NN0876 | 1 | |
| SULFATE ION | INACTIVE INGREDIENT | 7IS9N8KPMG | 1 |
Products#
Every source-derived product name is available through these pages.
- BIOPLASMA SPORT WITH ELECTROLYTES
- calcium fluoride, tribasic calcium phosphate, calcium sulfate anhydrous, ferrosoferric phosphate, potassium chloride, potassium phosphate, dibasic, magnesium phosphate, dibasic trihydrate, sodium chloride, sodium phosphate, dibasic, heptahydrate, sodium sulfate, and silicon dioxide
- LACTOSE
- CALCIUM CATION
- ANHYDROUS CITRIC ACID
- MAGNESIUM CATION
- MANNITOL
- SULFATE ION
- SORBITOL
- STEVIA REBAUDIUNA LEAF
- CALCIUM FLUORIDE
- FLUORIDE ION
- TRIBASIC CALCIUM PHOSPHATE
- PHOSPHATE ION
- CALCIUM SULFATE ANHYDROUS
- FERROSOFERRIC PHOSPHATE
- POTASSIUM CHLORIDE
- POTASSIUM CATION
- CHLORIDE ION
- POTASSIUM PHOSPHATE, DIBASIC
- MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE
- SODIUM CHLORIDE
- SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
- SODIUM CATION
- SODIUM SULFATE
- SODIUM SULFATE ANHYDROUS
- SILICON DIOXIDE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 54973-3122 | 54973-3122-1, 54973-3122-2 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION / SUBCUTANEOUS | 4.54 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | ELIXIR / ORAL | 90 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SUSPENSION / ORAL | 45000 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET / ORAL | 337.28 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRAVENOUS | 1276 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION, CONCENTRATE / INTRAVENOUS | 220 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SORBITOL | SORBITOL | 506T60A25R | GUM, CHEWING / ORAL | 6168 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SUSPENSION / ORAL | 400 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET / ORAL | 197 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | CAPSULE, LIQUID FILLED / ORAL | 360 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SUSPENSION, EXTENDED RELEASE / ORAL | 62 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET, ORALLY DISINTEGRATING / ORAL | 46 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 105 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / PARENTERAL | 200 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | PASTE / DENTAL | 14.6 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | EMULSION / TOPICAL | 7 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET / SUBLINGUAL | 50.5 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / SUBCUTANEOUS | 25 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SUSPENSION/ DROPS / ORAL | 15 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 35 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, COATED / ORAL | 177.7 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SOLUTION/ DROPS / AURICULAR (OTIC) | 1 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | POWDER, FOR SOLUTION / ORAL | 123 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION / INTRACARDIAC | 25 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION / INTRAVENOUS | 1152 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION / INTRAMUSCULAR | 101 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | GRANULE / ORAL | 1328 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / INTRAVENOUS | 772 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SPRAY / TOPICAL | 0.01 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / SUBCUTANEOUS | 4.7 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CAPSULE, DELAYED RELEASE / ORAL | 2043 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CAPSULE / ORAL | 1562 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 543 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | ELIXIR / ORAL | 833.3 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET, COATED / ORAL | 12.96 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, FILM COATED / ORAL | 2309 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SHAMPOO / TOPICAL | 0.07 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | SPRAY / NASAL | 49 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION / PERINEURAL | 0.02 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 1568 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION / SUBCUTANEOUS | 101 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | POWDER, FOR SUSPENSION / ORAL | 12000 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | POWDER / RESPIRATORY (INHALATION) | 6 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 300 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | GRANULE, FOR SUSPENSION / ORAL | 6000 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SYRUP / ORAL | 4370 mg/5ml | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SOLUTION, CONCENTRATE / INTRAVENOUS | 60 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | LOTION / TOPICAL | 10.7 %w/w | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 12 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 66d66d2b-86c7-e2c1-e053-2991aa0acced | cd808cfb-9bc5-453f-9f54-f568c16f3df3 | 2018-03-07 | Warnings | 66d66d2b-86c7-e2c1-e053-2991aa0acced cd808cfb-9bc5-453f-9f54-f568c16f3df3 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.